ELVN insider transaction filings
Enliven Therapeutics, Inc. — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-08-19. Screen ELVN transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-19 | 4 | Collins Helen Louise — CHIEF MEDICAL OFFICER | Option exercise (M): 5,000 @ $2.48 · Sale (S): 3,900 @ $58.37 · Sale (S): 1,100 @ $59.35 · Option exercise (M): 5,000 (derivative) @ $0 | EDGAR |
| 2026-08-19 | 4 | Hohl Benjamin — CHIEF FINANCIAL OFFICER | Sale (S): 4,630 @ $58.35 · Sale (S): 1,388 @ $59.35 | EDGAR |
| 2026-08-06 | 4 | Derynck Mika K — Director | Option exercise (M): 87,373 @ $2.48 · Option exercise (M): 27,567 @ $25.28 · Option exercise (M): 23,364 @ $14.85 · Option exercise (M): 20,491 @ $22.47 · Sale (S): 158,795 @ $60.21 · Option exercise (M): 87,373 (derivative) @ $0 · +3 more | EDGAR |
| 2026-07-21 | 4 | Hohl Benjamin — CHIEF FINANCIAL OFFICER | Option exercise (M): 1,072 @ $2.48 · Sale (S): 324 @ $49.97 · Sale (S): 369 @ $51.48 · Sale (S): 2,564 @ $52.32 · Sale (S): 2,638 @ $53.38 · Sale (S): 123 @ $53.87 · +1 more | EDGAR |
| 2026-07-21 | 4 | Collins Helen Louise — CHIEF MEDICAL OFFICER | Option exercise (M): 5,000 @ $2.48 · Sale (S): 231 @ $50.05 · Sale (S): 459 @ $51.55 · Sale (S): 2,063 @ $52.39 · Sale (S): 2,184 @ $53.42 · Sale (S): 63 @ $53.92 · +1 more | EDGAR |
| 2026-07-08 | 4 | Kunkel Lori Anne — Director | Sale (S): 4,111 @ $49.98 · Sale (S): 5,889 @ $50.84 | EDGAR |
| 2026-06-24 | 4 | ORBIMED ADVISORS LLC — 10% owner OrbiMed Capital GP VII LLC — 10% owner OrbiMed Genesis GP LLC — 10% owner | Sale (S): 24,846 @ $45.38 · Sale (S): 1,477 @ $45 · Sale (S): 787,024 @ $45.38 · Sale (S): 46,776 @ $45 | EDGAR |
| 2026-06-22 | 4 | Hohl Benjamin — CHIEF FINANCIAL OFFICER | Option exercise (M): 6,018 @ $2.48 · Sale (S): 1,379 @ $42.78 · Sale (S): 3,401 @ $43.86 · Sale (S): 1,238 @ $44.75 · Option exercise (M): 6,018 (derivative) @ $0 | EDGAR |
| 2026-06-22 | 4 | Collins Helen Louise — CHIEF MEDICAL OFFICER | Option exercise (M): 5,000 @ $2.48 · Sale (S): 1,268 @ $42.83 · Sale (S): 2,599 @ $43.87 · Sale (S): 1,133 @ $44.74 · Option exercise (M): 5,000 (derivative) @ $0 | EDGAR |
| 2026-06-17 | 4 | ORBIMED ADVISORS LLC — 10% owner OrbiMed Capital GP VII LLC — 10% owner OrbiMed Genesis GP LLC — 10% owner | Sale (S): 9,086 @ $45.02 · Sale (S): 272,322 @ $45.02 | EDGAR |
| 2026-06-09 | 4 | Kunkel Lori Anne — Director | Sale (S): 7,779 @ $34.28 · Sale (S): 1,867 @ $35.36 · Sale (S): 354 @ $35.82 | EDGAR |
| 2026-05-20 | 4 | Collins Helen Louise — CHIEF MEDICAL OFFICER | Option exercise (M): 5,000 @ $2.48 · Sale (S): 3,475 @ $39.53 · Sale (S): 1,302 @ $40.25 · Sale (S): 223 @ $41.21 · Option exercise (M): 5,000 (derivative) @ $0 | EDGAR |
| 2026-04-21 | 4 | Collins Helen Louise — CHIEF MEDICAL OFFICER | Option exercise (M): 5,000 @ $2.48 · Sale (S): 140 @ $45.81 · Sale (S): 2,419 @ $47.39 · Sale (S): 2,441 @ $48.06 · Option exercise (M): 5,000 (derivative) @ $0 | EDGAR |
| 2026-03-27 | 4 | Collins Helen Louise — CHIEF MEDICAL OFFICER | Option exercise (M): 40,000 @ $2.48 · Sale (S): 40,000 @ $35.10 · Option exercise (M): 40,000 (derivative) @ $0 | EDGAR |
| 2026-03-19 | 4 | Collins Helen Louise — CHIEF MEDICAL OFFICER | Option exercise (M): 5,000 @ $2.48 · Sale (S): 5,000 @ $27.76 · Option exercise (M): 5,000 (derivative) @ $0 | EDGAR |
| 2026-03-11 | 4 | Collins Helen Louise — CHIEF MEDICAL OFFICER | Option exercise (M): 29,871 @ $2.48 · Sale (S): 29,871 @ $30.02 · Option exercise (M): 10,129 @ $2.48 · Sale (S): 10,129 @ $30.19 · Option exercise (M): 29,871 (derivative) @ $0 · Option exercise (M): 10,129 (derivative) @ $0 | EDGAR |
| 2026-03-10 | 4 | Hohl Benjamin — CHIEF FINANCIAL OFFICER | Sale (S): 10,000 @ $29.58 | EDGAR |
| 2026-02-19 | 4 | Collins Helen Louise — CHIEF MEDICAL OFFICER | Option exercise (M): 45,000 @ $2.48 · Sale (S): 45,000 @ $26.17 · Option exercise (M): 45,000 (derivative) @ $0 | EDGAR |
| 2026-02-19 | 4 | Heyman Richard A. — Director | Sale (S): 1,230 @ $26.18 | EDGAR |
| 2026-02-17 | 4 | Patel Anish — CHIEF OPERATING OFFICER | Grant/award (A): 20,000 @ $0 · Grant/award (A): 120,000 (derivative) @ $0 | EDGAR |
| 2026-02-17 | 4 | Lyssikatos Joseph P — CHIEF SCIENTIFIC OFFICER | Grant/award (A): 18,750 @ $0 · Grant/award (A): 112,500 (derivative) @ $0 | EDGAR |
| 2026-02-17 | 4 | Hohl Benjamin — CHIEF FINANCIAL OFFICER | Grant/award (A): 25,000 @ $0 · Grant/award (A): 150,000 (derivative) @ $0 | EDGAR |
| 2026-02-17 | 4 | Derynck Mika K — Director | Grant/award (A): 17,126 (derivative) @ $0 | EDGAR |
| 2026-02-17 | 4 | Ballal Rahul D. — Director | Grant/award (A): 17,126 (derivative) @ $0 | EDGAR |
| 2026-02-17 | 4 | Collins Helen Louise — CHIEF MEDICAL OFFICER | Grant/award (A): 25,000 @ $0 · Grant/award (A): 150,000 (derivative) @ $0 | EDGAR |
| 2026-02-17 | 4 | Bauer Jake — Director | Grant/award (A): 17,126 (derivative) @ $0 | EDGAR |
| 2026-02-17 | 4 | Heyman Richard A. — Director | Grant/award (A): 19,234 (derivative) @ $0 | EDGAR |
| 2026-02-17 | 4 | Gupta Rishi — Director | Grant/award (A): 33,989 (derivative) @ $0 · Grant/award (A): 1,580 (derivative) @ $0 | EDGAR |
| 2026-02-17 | 4 | Kunkel Lori Anne — Director | Grant/award (A): 17,126 (derivative) @ $0 | EDGAR |
| 2026-02-17 | 4 | Garland J. Scott — Director | Grant/award (A): 1,427 (derivative) @ $0 | EDGAR |
| 2026-02-10 | 4 | Lyssikatos Joseph P — CHIEF SCIENTIFIC OFFICER | Sale (S): 5,000 @ $29.04 | EDGAR |
| 2026-01-22 | 4 | Lyssikatos Joseph P — CHIEF SCIENTIFIC OFFICER | Sale (S): 5,491 @ $26.37 · Sale (S): 14,509 @ $26.90 | EDGAR |
| 2026-01-22 | 4 | Heyman Richard A. — Director | Sale (S): 512 @ $26.46 · Sale (S): 718 @ $26.96 | EDGAR |
| 2026-01-13 | 4 | Patel Anish — CHIEF OPERATING OFFICER | Sale (S): 48,057 @ $27.98 · Sale (S): 243 @ $28.50 | EDGAR |
| 2026-01-12 | 4 | Lyssikatos Joseph P — CHIEF SCIENTIFIC OFFICER | Sale (S): 7,500 @ $20.13 · Sale (S): 33,802 @ $24.92 · Sale (S): 41,198 @ $24.90 · Sale (S): 50,000 @ $29.13 | EDGAR |
| 2026-01-12 | 4 | Heyman Richard A. — Director | Sale (S): 1,620 @ $25 · Sale (S): 8,015 @ $25.04 · Sale (S): 4,285 @ $25.00 | EDGAR |
| 2026-01-09 | 4 | Garland J. Scott — Director | Grant/award (A): 59,372 (derivative) @ $0 | EDGAR |
| 2025-12-23 | 4 | Lyssikatos Joseph P — CHIEF SCIENTIFIC OFFICER | Sale (S): 5,000 @ $16.84 | EDGAR |
| 2025-12-23 | 4 | Hohl Benjamin — CHIEF FINANCIAL OFFICER | Option exercise (M): 13,000 @ $2.48 · Option exercise (M): 13,000 (derivative) @ $0 | EDGAR |
| 2025-12-19 | 4 | Kunkel Lori Anne — Director | Option exercise (M): 15,958 @ $1.12 · Option exercise (M): 15,958 (derivative) @ $0 | EDGAR |
| 2025-12-12 | 4 | Fair Richard A. — PRESIDENT AND CEO, Director | Grant/award (A): 875,000 (derivative) @ $0 | EDGAR |
| 2025-12-10 | 4 | Patel Anish — CHIEF OPERATING OFFICER | Sale (S): 4,958 @ $20.76 · Sale (S): 1,705 @ $21.78 | EDGAR |
| 2025-11-21 | 4 | Lyssikatos Joseph P — CHIEF SCIENTIFIC OFFICER | Sale (S): 12,008 @ $22.30 · Sale (S): 492 @ $23.09 | EDGAR |
| 2025-11-19 | 4 | Kintz Samuel — PRESIDENT AND CEO, Director | Sale (S): 12,500 @ $21.82 | EDGAR |
| 2025-11-12 | 4 | Patel Anish — CHIEF OPERATING OFFICER | Sale (S): 6,054 @ $17.35 · Sale (S): 613 @ $17.94 | EDGAR |
| 2025-10-22 | 4 | Lyssikatos Joseph P — CHIEF SCIENTIFIC OFFICER | Sale (S): 12,500 @ $22.08 | EDGAR |
| 2025-10-21 | 4 | Kintz Samuel — PRESIDENT AND CEO, Director | Sale (S): 12,500 @ $21.33 | EDGAR |
| 2025-10-09 | 4 | Patel Anish — CHIEF OPERATING OFFICER | Sale (S): 6,667 @ $20.10 | EDGAR |
| 2025-10-01 | 4 | Hohl Benjamin — CHIEF FINANCIAL OFFICER | Option exercise (M): 3,250 @ $2.48 · Sale (S): 3,250 @ $20.40 · Option exercise (M): 3,250 (derivative) @ $0 | EDGAR |
| 2025-09-30 | 4 | Kintz Samuel — PRESIDENT AND CEO, Director | Sale (S): 3,700 @ $20.06 | EDGAR |
Recent 8-K events — Enliven Therapeutics, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-05 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-12 | 8-K | 1.01 — Entry into a Material Definitive Agreement 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-11 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-10 | 8-K | 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-07 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-03 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-07 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-12-11 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-13 | 8-K/A | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-12 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=ELVN returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →